// App-Quantinova.ai

3111 : Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the MEDALIST Study

Researchers

Presenter

  • Rami S. Komrokji

Principal Investigators

  • Pierre Fenaux

  • Guillermo Garcia-Manero

  • Ghulam J. Mufti

  • Valeria Santini

  • Maria Diez-Campelo

  • Carlo Finelli

  • Joseph G. Jurcic

  • Peter L. Greenberg

  • Mikkael A. Sekeres

  • Amer M. Zeidan

  • Amy E. DeZern

  • Michael R. Savona

  • Jeevan K. Shetty

  • Rodrigo Ito

  • George Zhang

  • Xianwei Ha

  • Daniel Sinsimer

  • Jay T. Backstrom

  • Amit Verma

Medical Centers

  • Moffitt Cancer Center, Tampa, FL

  • Dept. Hematology and Cell Therapy,University Hospital Leipzig,Leipzig,Germania

  • Service d'Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris and Université Paris 7,Paris,France

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Haematological Medicine, King's College London, London, United Kingdom

  • Radiotherapy Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy

  • Hematology Department, Institute of Biomedical Research of Salamanca, University Hospital of Salamanca,Salamanca,Espagne

  • Department of Oncology and Hematology, S. Orsola‐Malpighi University Hospital, Bologna, Italy

  • Division of Hematology/Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY

  • Stanford University Cancer Institute, Stanford, CA

  • Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH

  • Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Vanderbilt-Ingram Cancer Center, Vanderbilt University, School of Medicine, Nashville, TN

  • Celgene International Sàrl, a Bristol Myers Squibb Company, Boudry, Switzerland

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Acceleron Pharma, Cambridge, MA

  • Department of Medical Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY

Locations

  • United States

  • Germany

  • France

  • United Kingdom

  • Italy

  • Spain

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myeloid neoplasms

  • Alpha-thalassemia myelodysplasia syndrome

Biomarkers

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

  • Thrombocytosis

Drug/Treatment

  • Erythropoietin

  • luspatercept

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT02631070

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved